Pharmacokinetic Assessment of the Absorption of Estradiol in Postmenopausal Women With Atrophic Vaginitis

Inclusion Criteria: * Subjects who are able to use German language in speaking and writing * Postmenopausal women with at least 5 years after last menstruation, or bilateral oophorectomy performed two years or more prior to the time of screening * Serum FSH (Follicle Stimulating Hormone) levels above 40 mIU/ml and estradiol below 20 pg/ml * Maximum 5% superficial cells as assessed by evaluation of vaginal cytology * Endometrial thickness below 4.0 mm (double layer), as measured by transvaginal ultrasound (if applicable) * Availability of a normal mammogram within one year prior to trial start * Good general health as assessed by the Investigator and based on medical history, and physical and laboratory examinations Exclusion Criteria: * Known or suspected allergy to trial product or related products * Known, suspected or past history of breast cancer * Known, suspected or past estrogen dependent neoplasia e.g. endometrial cancer * Endometrial hyperplasia or endometrial polyps diagnosed during the screening period * Abnormal genital bleeding of unknown etiology * Previous estrogen and/ or progestin hormone replacement therapy